Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2025 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
May 15, 2025 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

– Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system...
March 31, 2025 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since...
February 26, 2025 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
February 18, 2025 10:21 ET | Source: Cabaletta Bio

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining...
February 18, 2025 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining...
February 11, 2025 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
January 29, 2025 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
January 13, 2025 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and...
November 26, 2024 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...